Journal ArticleDOI
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)
Philip S. Helliwell,Philip S. Helliwell,Oliver FitzGerald,Jaap Fransen,Dafna D. Gladman,Gerald G Kreuger,Kristina Callis-Duffin,Neil McHugh,Philip J. Mease,Vibeke Strand,Robin Waxman,Valderílio Feijó Azevedo,Adriana Beltran Ostos,Sueli Carneiro,Alberto Cauli,Luis R Espinoza,John A. Flynn,Nada Hassan,Paul J. Healy,Eduardo Kerzberg,Yun Jong Lee,Ennio Lubrano,Antonio Marchesoni,Helena Marzo-Ortega,Giovanni Porru,Elvia G. Moreta,Peter Nash,Helena Raffayova,Roberto Ranza,Siba P. Raychaudhuri,Euthalia Roussou,Raphael Scarpa,Yeong Wook Song,Enrique R. Soriano,Paul P. Tak,Ilona Ujfalussy,Kurt de Vlam,Jessica A. Walsh +37 more
Reads0
Chats0
TLDR
Two new composite measures to assess disease activity in PsA have been developed by multiple linear regression and empirically, utilising physician-defined cut-offs for disease activity, and area under the receiver operating curves (AUC) were generally smaller.Abstract:
Objective To develop new composite disease activity indices for psoriatic arthritis (PsA). Methods Data from routine clinic visits at multiple centres were collected in a systematic manner. Data included all domains identified as important in randomised controlled trials in PsA. Decisions to change treatment were used as surrogates for high disease activity. New indices were developed by multiple linear regression (psoriatic arthritis disease activity score: PASDAS) and empirically, utilising physician-defined cut-offs for disease activity (arithmetic mean of desirability functions: AMDF). These were compared with existing composite measures: Composite Psoriatic arthritis Disease Activity Index (CPDAI), Disease Activity for PSoriatic Arthritis (DAPSA), and Disease Activity Score for rheumatoid arthritis (DAS28). Results 161/503 (32%) subjects had treatment changes. Although all measures performed well, compared with existing indices, PASDAS was better able to discriminate between high and low disease activity (area under receiver operating curves (ROC)) curve with 95% CI: PASDAS 0.773 (0.723, 0.822); AMDF 0.730 (0.680, 0.780); CPDAI 0.719 (0.668, 0.770); DAPSA 0.710 (0.654, 0.766); DAS28 0.736 (0.680, 0.792). All measures were able to discriminate between disease activity states in patients with oligoarthritis, although area under the receiver operating curves (AUC) were generally smaller. In patients with severe skin disease (psoriasis area and severity index >10) both nonparametric and AUC curve statistics were nonsignificant for all measures. Conclusions Two new composite measures to assess disease activity in PsA have been developed. Further testing in other datasets, including comparison with existing measures, is required to validate these instruments.read more
Citations
More filters
Advances in the management of psoriatic
Carlo Palazzi,Angela Padula +1 more
TL;DR: Psoriatic arthritis management must now use improved measures to predict patient outcomes and define remission, and develop better-targeted therapies.
Journal ArticleDOI
Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies
Dennis McGonagle,Iain B. McInnes,Atul Deodhar,Georg Schett,May Shawi,Soumya D. Chakravarty,A. Kollmeier,Xie L. Xu,Shihong Sheng,Stephen Xu,Christopher T. Ritchlin,Proton Rahman,Philip J. Mease +12 more
TL;DR: In this article , the authors investigate associations between dactylitis resolution and other outcomes through 1 year and show that patients treated with guselkumab compared with placebo had significantly higher rates of resolution.
Journal ArticleDOI
Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cross-sectional study
Fabian Proft,Julia Schally,H. Brandt,J. Brandt-Juergens,Gerd R Burmester,Hildrun Haibel,Henriette Käding,Kirsten Karberg,S. Lüders,B. Muche,Mikhail Protopopov,J. Rademacher,Valeria Rios Rodriguez,Murat Torgutalp,Maryna Verba,S. Zinke,Denis Poddubnyy +16 more
TL;DR: In this paper , the authors evaluated the agreement of disease activity categories between clinical DAPSA and quick quantitative C reactive protein (qCRP) assay (Q-DAPSA) in patients with psoriatic arthritis.
Compléments : Que signifie l’évaluation globale par le patient dans le rhumatisme psoriasique ? Une analyse de 223 patients issus de l’étude d’élaboration du Psoriatic Arthritis Impact of Disease (PsAID)
Sandra Tälli,Adrien Etcheto,Bruno Fautrel,A. Balanescu,Jürgen Braun,Juan D. Cañete,Kurt de Vlam,Maarten de Wit,Turid Heiberg,Philip S. Helliwell,Umut Kalyoncu,Uta Kiltz,Mara Maccarone,Dora Niedermayer,Kati Otsa,Rossana Scrivo,Josef S. Smolen,Tanja Stamm,Douglas J. Veale,T K Kvien,Laure Gossec +20 more
TL;DR: L’evaluation globale par le patient dans le rhumatisme psoriasique s’expliquait principalement par les composantes physiques mais egalement psychologiques de the maladie.
Journal ArticleDOI
Effectiveness of anti‐interleukin‐23 therapy in psoriatic arthritis: A pilot prospective real‐world study
Tumay Ak,Sera Nur Yucesoy Temiz,Meliksah Taner,Ali Y. Ayla,Ahmet Atıl Aygun,Burhan Engin,Günay Can,Serdal Ugurlu +7 more
TL;DR: In this article , the effectiveness of interleukin (IL)23 inhibitors in psoriatic arthritis (PsA) at weeks 12 and 24 in a real-world setting was evaluated.
References
More filters
Journal ArticleDOI
Measurement of patient outcome in arthritis.
TL;DR: A structure for representation of patient outcome is presented, together with a method for outcome measurement and validation of the technique in rheumatoid arthritis, and these techniques appear extremely useful for evaluation of long term outcome of patients with rheumatic diseases.
Journal ArticleDOI
Severe psoriasis--oral therapy with a new retinoid.
T. Fredriksson,Ulf Pettersson +1 more
TL;DR: Ro 10--9359 proved to be an extremely potent antipsoriatic drug and a more than 90% reduction of psoriatic lesions could be seen in 10 patients out of 20 after 4-8 weeks of treatment.
Journal ArticleDOI
Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria
A.M. van Gestel,M.L.L. Prevoo,M.A. van 't Hof,M. H. Van Rijswijk,L. B. A. Van De Putte,P.L.C.M. van Riel +5 more
TL;DR: EULAR response criteria showed better construct and discriminant validity than did the ACR and the WHO/ILAR response criteria for RA and the World Health Organization and International League Against Rheumatism criteria.
Journal ArticleDOI
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
TL;DR: Etanercept offers patients with psoriatic arthritis and psoriasis a new therapeutic option for control of their disease.
Journal Article
Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index
TL;DR: Five clinical measurements provide a composite index (BASMI) and define disease status in AS, which is quick, reproducible and sensitive to change across the disease spectrum.
Related Papers (5)
Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
Laure Gossec,Josef S Smolen,Sofia Ramiro,M. de Wit,Maurizio Cutolo,Maxime Dougados,Paul Emery,Robert Landewé,Sue Oliver,Daniel Aletaha,Neil Betteridge,Jürgen Braun,G.-R. Burmester,Juan D. Cañete,Nemanja Damjanov,Oliver FitzGerald,Emma Haglund,P S Helliwell,Tore K Kvien,Rik Lories,Thomas A. Luger,Mara Maccarone,Helena Marzo-Ortega,Dennis McGonagle,Iain B. McInnes,I. Olivieri,Karel Pavelka,Georg Schett,Joachim Sieper,F. Van den Bosch,Douglas J. Veale,Jürgen Wollenhaupt,Angela Zink,D. van der Heijde +33 more
Treatment recommendations for psoriatic arthritis
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
Laura C. Coates,Arthur Kavanaugh,Philip J. Mease,Enrique R. Soriano,Maria Laura Acosta-Felquer,April W. Armstrong,Wilson Bautista-Molano,Wolf-Henning Boehncke,Willemina Campbell,Alberto Cauli,Luis R. Espinoza,Oliver FitzGerald,Dafna D. Gladman,Alice B. Gottlieb,Philip S. Helliwell,M. Elaine Husni,Thorvardur Jon Love,Ennio Lubrano,Neil McHugh,Peter Nash,Alexis Ogdie,Ana Maria Orbai,Andrew Parkinson,Denis O'Sullivan,Cheryl F. Rosen,Sergio Schwartzman,Evan L. Siegel,Sergio Toloza,William Tuong,Christopher T. Ritchlin +29 more